Key clinical point: Bridging therapy with hypomethylating agents (HMAs) did not provide long-term survival benefit in patients with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Major finding: Overall survival was not significantly different among patients who received HMAs vs. best supportive care before allo-HSCT (hazard ratio, 0.86; P = .32).
Study details : Findings are from a meta-analysis of 7 retrospective studies including 820 patients with MDS, of which 395 patients received HMAs before allo-HSCT and the remaining patients received best supportive care.
Disclosures: The study was funded by Youth Science Foundation of National Natural Science Foundation of China. The authors declared no potential conflicts of interest.
Source: Liu L et al. Clin Exp Med. 2021 Apr 17. doi: 10.1007/s10238-021-00712-0 .